Brexit – will all the medicines get to the patients?
Posted: 2 November 2018 | Paul Gershlick (Partner and Head of Pharma & Life Sciences - VWV) | No comments yet
Two years after the UK narrowly voted to exit the EU it remains unclear as to what this may involve. In July 2016, Theresa May stated that “Brexit means Brexit.” But what exactly did that mean?
It means that the UK is leaving the EU, but it does not explain the UK’s future relationship with the trading bloc. Options abound, such as Hard Brexit, soft Brexit, the hardest-of-hard Brexit, regulatory alignment, and crash-out-without-a-deal Brexit. But with no sign of surety in sight, businesses remain uncertain whether to stick or twist – spend lots of money or wait to see what happens?
The UK Government’s Chequers Plan and White Paper in July were widely praised by the pharma industry, which viewed it as a big step forward in maintaining regulatory alignment with the EU and, notably, a unilateral statement of intent to work with and accept the rules of the European Medicines Agency (EMA). The offer also included a desire to contribute towards the EMA’s costs, and mutual recognition of qualified persons (QP) and qualified persons for pharmacovigilance (QPPV) in each territory, as well as the regulatory experts at the Medicines and Healthcare products Regulatory Agency (MHRA).
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!